NXTC NXTC
Company Profile ↓Company Overview
NXTC (NXTC) is a publicly traded company listed on with a market capitalization of $18.40M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.15.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +4.17% |
| 6 Months: | -53.12% |
| 3 Months: | -43.67% |
| 1 Month: | +194.94% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)56.04 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 63.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 1.36M | 1.40M | 1.58M | 22.38M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 11.62M | 27.29M | 8.95M | 9.76M | 10.11M |
| Operating Income | -5.01M | -5.30M | -5.82M | -6.82M | -8.96M | -9.70M | 8.21M | -15.80M | -17.40M | -17.23M | -17.95M | -18.51M | -20.77M | -18.13M | -19.24M | -17.07M | -19.16M | -15.62M | -18.30M | -16.49M | -12.49M | - | -11.62M | -27.29M | -8.95M | -9.76M | -10.11M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -10.97M | -26.66M | -8.41M | -9.39M | -9.82M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -10.98M | -26.81M | -8.62M | -9.44M | -9.80M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -5.00M | -5.23M | -5.71M | -6.16M | -8.22M | -8.43M | 9.73M | -14.51M | -16.37M | -16.53M | -17.99M | -17.93M | -20.60M | -17.92M | -18.91M | -16.10M | -17.86M | -14.30M | -17.11M | -15.40M | -11.54M | - | -10.98M | -26.81M | -8.62M | -9.44M | -9.80M |
| Diluted EPS | - | - | - | -4.46 | - | - | 0.33 | - | -0.59 | -0.60 | -0.65 | -0.65 | -0.74 | -0.65 | -0.68 | -0.58 | -0.64 | -0.51 | -0.61 | -6.61 | -4.95 | - | -4.70 | -11.29 | -3.22 | - | -1.87 |
| R&D Expense | 4.21M | 4.43M | 4.89M | 6.51M | 7.64M | 8.66M | 10.58M | 11.13M | 12.74M | 12.39M | 11.95M | 13.60M | 15.02M | 12.82M | 13.53M | 11.65M | 13.45M | 11.01M | 11.40M | 12.42M | 8.77M | - | 7.90M | 24.09M | 6.14M | - | 6.83M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | 6.35M | 22.38M | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | 75.91M | 67.64M | 57.21M | 57.62M |
| Operating Income | -23.20M | -37.48M | -41.23M | -70.77M | -75.91M | -67.64M | -57.21M | -57.62M |
| EBITDA | - | - | - | - | -71.78M | -63.95M | -54.34M | -55.43M |
| Interest Expense | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | -74.73M | -62.72M | -55.65M | -55.84M |
| Tax Provision | - | - | - | - | - | - | - | - |
| Net Income | -22.80M | -33.74M | -36.60M | -69.39M | -74.73M | -62.72M | -55.65M | -55.84M |
| Diluted EPS | - | - | -1.33 | -2.51 | -32.28 | -27.00 | -23.88 | -19.65 |
| R&D Expense | 19.79M | 34.22M | 46.55M | 50.19M | 54.20M | 47.93M | 41.49M | 44.92M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 147.63M | 356.17M | 306.64M | - | 184.16M | 128.04M | 80.86M | 50.18M |
| Current Assets | - | - | - | - | - | 163.98M | 112.72M | 71.81M | 43.75M |
| Cash & Equivalents | - | 135.17M | 34.09M | 32.77M | - | 26.63M | 13.08M | 27.73M | 25.98M |
| Inventory | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | 32.35M | 34.68M | 12.92M | - | 16.63M | 13.62M | 15.39M | 15.24M |
| Current Liabilities | - | 10.30M | 15.04M | 10.32M | - | 9.13M | 6.88M | 9.57M | 10.57M |
| Long Term Debt | - | 73.00K | 3.33M | 1.81M | - | - | - | - | - |
| Total Debt | - | - | - | - | - | 7.12M | 6.61M | 5.95M | 5.15M |
| Total Equity | -24.41M | -46.94M | 321.48M | 293.72M | - | 167.53M | 114.42M | 65.47M | 34.94M |
| Shares Outstanding | - | - | - | - | - | 2.31M | 2.33M | 2.33M | 3.51M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 7.99M | -35.62M | -44.95M | - | -53.89M | -52.97M | -40.80M | -49.61M |
| Investing Cash Flow | -3.06M | -303.92M | 43.52M | - | 67.98M | 39.27M | 55.31M | 25.56M |
| Financing Cash Flow | 121.42M | 243.04M | -1.42M | - | 200.00K | 154.00K | 144.00K | 22.31M |
| Capital Expenditure | -3.06M | -3.37M | -7.13M | -2.36M | -2.12M | -820.00K | -474.00K | - |
| Free Cash Flow | 4.93M | -38.99M | -52.09M | - | -56.00M | -53.79M | -41.28M | -49.61M |
| Net Change in Cash | - | - | - | - | 14.29M | -13.55M | 14.64M | -1.75M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - |
| Operating Margin % | - | -590.5% | -184.2% | - | - | - | - | - |
| Net Margin % | - | -531.5% | -163.6% | - | - | - | - | - |
| ROE % | 48.6% | -10.5% | -12.5% | - | -44.6% | -54.8% | -85.0% | -159.8% |
| ROCE % | -16.9% | -11.0% | -13.9% | - | -43.4% | -55.8% | -80.2% | -145.4% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NXTC
$NXTC stock is down 13% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxPR3JXcTFma2R6bUxwMlgwbkZmMmwtRmI3SXlxR25yNEx2TXhHV0l6YXprd2w3RU55Ym9fNmhqbmttNjV6YVNEemdWR0Y5bk93TG5zakV4LUJMZ250UDRISVJrQVBVN0QzMFRxdXBBcDZic2pfOFBvSFJ1RUM2M1cxWGFpMkpXa0RkQXBKcF…
ADAR1-managed funds buy 329,153 shares of NextCure (NXTC) - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxQeUtCbjc4QzMyNEliM3pzSWNOR3c3Zno0SUVOeUhDb2FpSFdHazlJMTVEeGZLdmtSNjg5bno0QkJQUVloYlAyNFF0cXpwYTl3VnFsUnJRY2doMDBOMVZtXzBZZDA2UDFQanpfb1RrRnhvZHo5YU1KcXZ2eHF3LTdkRTgxMlBDVFJ2SWFab0…
Adar1 Capital Management buys $1.6m in NextCure (NXTC) shares - Investing.com
<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxOSFVqUWR3NWUwakhSN3RjVHNweFRkdUxsZ2ktaHFUNnVnZUJuU3YzX2hiaWZndzFqRThTWUFzb1dqTFVoNlg0azM2MDNJd1NuSTlYbC1HLUtRanVBOUQyRjFLRDA4dkxETDI2dUFldG82eE1lX2lvSTF1UTMycFd4NV8xYzgwUm9HTlpMTk…
NextCure, Inc. Revenue Breakdown – NASDAQ:NXTC - TradingView
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE9iWTZsUkpmX0NzRWJRSlZWMnBmdjY4cWE4MkZRX0pqYk81SGYtUGNTTW8teGdrcFY2WmxKTlFDUGRib1d3S2h3NjZXa1NHemI1Mm9xc1AtSDJxVy0tNEx1dW1TS0F3eHhsd2RlcjlBeDRZUGQ2eFlV?oc=5" target="_blank">NextCur…
NXTC Stock Alert: Halper Sadeh LLC is Investigating Whether NextCure, Inc. is Obtaining a Fair Price for its Shareholders - Business Wire
<a href="https://news.google.com/rss/articles/CBMihwJBVV95cUxObFBjVWJNblhxTGRpNHVCRXFHOXFhbUdOLUZVa3d3eXZVS29yTXNhUTR0TldGQjJwSkNaMThUTWdCZ2FVUWxwOGxYeHZiMGZwX3A1VkgzRjlvTl9weV9rY1ZGWTJadlpXdTRoSXRndDQxZFFPTXFJb29nRGZPOHBoVWlyLXpGM0ZBb1dkdl…
Are CRNX, VEEE, NXTC, TCBK Obtaining Fair Deals for their Shareholders? - Morningstar
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxORV90S2dRVlVuN2xvejEybkk3Y0RHXzk4Z3dYN3JiQXBfSWRnMzBqeW03cDJ1b1FYOEFobFRmUl9ybGpaOUphbE54b1N1dThMaVk4WTVmNExoM295aTEtS0l5ZWd2QzBWTlJxVEhhVXVid1p4b3RMZjZIZ0FTNVRhS2ExcDZuc2ItTTVSc3…
NXTC — Frequently Asked Questions
What is the current share price of NXTC?
As of 2026-08-05 17:25 PDT, NXTC trades at $5.25 on NASDAQ/NYSE. Its 52-week range is $1.60 to $14.27.
What is the market capitalisation of NXTC?
NXTC has a market capitalisation of $18.40M on NASDAQ/NYSE.
What is the P/E ratio of NXTC?
NXTC trades at a trailing price-to-earnings (P/E) ratio of -0.27. Its price-to-book (P/B) ratio is 0.53.
Is NXTC a good stock to buy?
This page provides a data-driven analysis of NXTC, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.